Clin­i­cal tri­al trans­paren­cy im­proves at (some) bio­phar­mas as J&J, Sanofi lead a pack trailed by Valeant and Al­ler­gan

Drug mak­ers ap­pear to be more trans­par­ent with their clin­i­cal tri­al da­ta than they used to be, ac­cord­ing to a new analy­sis by a coali­tion of re­searchers. But not all phar­mas are not equal­ly forth­right.

The group, led by not-for-prof­it Bioethics In­ter­na­tion­al, looked at clin­i­cal tri­al reg­is­tra­tion, re­sults re­port­ing, clin­i­cal study re­port syn­op­sis shar­ing and jour­nal pub­li­ca­tion rates for new drugs ap­proved by the FDA in 2014. Specif­i­cal­ly, they ze­roed in on large phar­ma­ceu­ti­cal com­pa­nies, and ranked them by trans­paren­cy met­rics.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER